Lesiones cutáneas y terapia biológica con antagonistas del factor de necrosis tumoral

Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum, 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W Weinblatt, 1999, A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N Engl J Med, 340, 253, 10.1056/NEJM199901283400401 Nam, 2010, Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA, Ann Rheum Dis, 69, 976, 10.1136/ard.2009.126573 Karampetsou, 2010, TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future, Qjm, 103, 917, 10.1093/qjmed/hcq152 Rosenblum, 2011, Anti-TNF therapy: safety aspects of taking the risk, Autoimmun Rev, 10, 563, 10.1016/j.autrev.2011.04.010 Singh, 2011, Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, CD008794 Sfikakis, 2005, Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction, Arthritis Rheum, 52, 2513, 10.1002/art.21233 Devos, 2003, Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy, Dermatology, 206, 388, 10.1159/000069965 Lee, 2007, Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists, Br J Dermatol, 156, 486, 10.1111/j.1365-2133.2007.07682.x Flendrie, 2005, Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study, Arthritis Res Ther, 7, R666, 10.1186/ar1724 Keystone, 2004, Once-weekly administration of 50mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 50, 353, 10.1002/art.20019 Weinblatt, 2003, Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial, Arthritis Rheum, 48, 35, 10.1002/art.10697 Keystone, 2008, Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Arthritis Rheum, 58, 3319, 10.1002/art.23964 Keystone, 2009, Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study, Ann Rheum Dis, 68, 789, 10.1136/ard.2008.099010 Salliot, 2007, Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients, Rheumatology (Oxford), 46, 327, 10.1093/rheumatology/kel236 Dixon, 2006, Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register, Arthritis Rheum, 54, 2368, 10.1002/art.21978 Solomon, 2008, The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence, Arthritis Rheum, 58, 919, 10.1002/art.23396 Bernatsky, 2010, Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists, J Rheumatol, 37, 928, 10.3899/jrheum.091107 Curtis, 2007, Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists, Arthritis Rheum, 56, 1125, 10.1002/art.22504 Listing, 2005, Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis Rheum, 52, 3403, 10.1002/art.21386 Garcia-Doval, 2010, Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists, Ann Rheum Dis, 69, 1751, 10.1136/ard.2009.125658 Strangfeld, 2009, Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents, Jama, 301, 737, 10.1001/jama.2009.146 Smitten, 2007, The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom, Arthritis Rheum, 57, 1431, 10.1002/art.23112 Leombruno, 2009, The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events, Ann Rheum Dis, 68, 1136, 10.1136/ard.2008.091025 Bongartz, 2006, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials, Jama, 295, 2275, 10.1001/jama.295.19.2275 Askling, 2005, Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists, Ann Rheum Dis, 64, 1414, 10.1136/ard.2004.033241 Askling, 2005, Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists, Ann Rheum Dis, 64, 1421, 10.1136/ard.2004.033993 Carmona, 2011, Cancer in patients with rheumatic diseases exposed to TNF antagonists, Semin Arthritis Rheum, 41, 71, 10.1016/j.semarthrit.2010.08.005 Balkwill, 2006, TNF-alpha in promotion and progression of cancer, Cancer Metastasis Rev, 25, 409, 10.1007/s10555-006-9005-3 Mariette, 2011, Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis, Ann Rheum Dis, 70, 1895, 10.1136/ard.2010.149419 Wolfe, 2007, Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study, Arthritis Rheum, 56, 2886, 10.1002/art.22864 Chakravarty, 2005, Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors, J Rheumatol, 32, 2130 Klareskog, 2006, A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs, Ann Rheum Dis, 65, 1578, 10.1136/ard.2005.038349 Mercer, 2012, The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register, Ann Rheum Dis, 21, 869, 10.1136/annrheumdis-2011-200622 Le Blay, 2012, Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled tials, J Rheumatol, 39, 712, 10.3899/jrheum.110982 Katoulis, 2010, Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation, Dermatology, 221, 9, 10.1159/000300136 Kowalzick, 2009, Long term treatment of psoriasis with TNF-alpha antagonists Occurrence of malignant melanoma, Hautarzt, 60, 655, 10.1007/s00105-008-1695-8 Khan, 2009, Primary cutaneous melanoma: a complication of infliximab treatment, Clin Exp Dermatol, 34, 524, 10.1111/j.1365-2230.2008.02970.x Katsanos KH, Christodoulou DK, Zioga A, Tsianos EV. Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence? Inflamm Bowel Dis 2003; 9: 279. Bovenschen, 2006, Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals, Br J Dermatol, 154, 880, 10.1111/j.1365-2133.2006.07189.x Buchbinder, 2008, Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate, Arthritis Rheum, 59, 794, 10.1002/art.23716 Brown, 2002, Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration, Arthritis Rheum, 46, 3151, 10.1002/art.10679 Koens, 2009, Cutaneous gamma/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis, Acta Derm Venereol, 89, 653, 10.2340/00015555-0728 Lourari, 2009, Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases, J Eur Acad Dermatol Venereol, 23, 967, 10.1111/j.1468-3083.2008.03074.x Sanli, 2007, Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy, J Drugs Dermatol, 6, 834 Dauendorffer, 2007, Sezary syndrome in a patient receiving infliximab for ankylosing spondylitis, Br J Dermatol, 156, 742, 10.1111/j.1365-2133.2006.07713.x Gossec, 2012, European League against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies, Ann Rheum Dis, 71, 4, 10.1136/annrheumdis-2011-200350 Reich, 2012, Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials, Br J Dermatol, 166, 179, 10.1111/j.1365-2133.2011.10583.x Harrison, 2009, Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register, Ann Rheum Dis, 68, 209, 10.1136/ard.2007.087288 Wollina, 2008, Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients, Am J Clin Dermatol, 9, 1, 10.2165/00128071-200809010-00001 Ko, 2009, Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases, J Dermatolog Treat, 20, 100, 10.1080/09546630802441234 Basavaraj, 2010, The role of drugs in the induction and/or exacerbation of psoriasis, Int J Dermatol, 49, 1351, 10.1111/j.1365-4632.2010.04570.x Collamer, 2010, Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis, Semin Arthritis Rheum, 40, 233, 10.1016/j.semarthrit.2010.04.003 Grinblat, 2008, The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review, Semin Arthritis Rheum, 37, 251, 10.1016/j.semarthrit.2007.05.004 De Gannes, 2007, Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions, Arch Dermatol, 143, 223, 10.1001/archderm.143.2.223 Collamer, 2008, Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action, Arthritis Rheum, 59, 996, 10.1002/art.23835 Michaelsson, 2005, Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct, Br J Dermatol, 153, 1243, 10.1111/j.1365-2133.2005.06977.x Shmidt, 2011, Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: The Mayo Clinic experience, 1998 to 2010, J Am Acad Dermatol Mocciaro, 2009, Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case, Am J Gastroenterol, 104, 2867, 10.1038/ajg.2009.396 Klein, 2010, Psoriatic skin lesions induced by certolizumab pegol, Arch Dermatol, 146, 1055, 10.1001/archdermatol.2010.225 Fiorentino, 2007, The Yin and Yang of TNF-{alpha} inhibition, Arch Dermatol, 143, 233, 10.1001/archderm.143.2.233 Spencer, 1994, Pustular eruption after drug exposure: is it pustular psoriasis or a pustular drug eruption, Br J Dermatol, 130, 514, 10.1111/j.1365-2133.1994.tb03389.x Aeberli, 2005, Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors, Rheumatology (Oxford), 44, 172, 10.1093/rheumatology/keh437 Pirard, 2006, Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview, Dermatology, 213, 182, 10.1159/000095033 Dass, 2007, Development of psoriasis after B cell depletion with rituximab, Arthritis Rheum, 56, 2715, 10.1002/art.22811 Mielke, 2008, Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma, Ann Rheum Dis, 67, 1056, 10.1136/ard.2007.080929 Bonnet, 2010, [Cutaneous events during anti-TNF alpha therapy: a prospective observational study of 41 cases], Ann Dermatol Venereol, 137, 12, 10.1016/j.annder.2009.12.003 Roux, 2007, New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect, J Rheumatol, 34, 434 De Rycke, 2005, The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications, Lupus, 14, 931, 10.1191/0961203305lu2240rr Atzeni, 2005, Autoimmunity, anti-TNF-alpha agents, Ann N Y Acad Sci, 1051, 559, 10.1196/annals.1361.100 Ferraro-Peyret, 2004, Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study, Arthritis Res Ther, 6, R535, 10.1186/ar1440 Williams, 2011, TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists, Int J Dermatol, 50, 619, 10.1111/j.1365-4632.2011.04871.x Wetter, 2009, Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic, Mayo Clin Proc, 84, 979, 10.1016/S0025-6196(11)60668-X Williams, 2009, Anti-TNF-induced lupus, Rheumatology (Oxford), 48, 716, 10.1093/rheumatology/kep080 Ramos-Casals, 2007, Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases, Medicine (Baltimore), 86, 242, 10.1097/MD.0b013e3181441a68 Exarchou, 2009, Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors, Scand J Rheumatol, 38, 328, 10.1080/03009740902922612 Stratigos, 2004, Discoid lupus erythematosus-like eruption induced by infliximab, Clin Exp Dermatol, 29, 150, 10.1111/j.1365-2230.2004.01471.x Costa, 2008, Drug-induced lupus due to anti-tumor necrosis factor alpha agents, Semin Arthritis Rheum, 37, 381, 10.1016/j.semarthrit.2007.08.003 Vezzoli, 2011, Cutaneous lupus erythematosus induced by adalimumab, J Dermatol, 38, 283, 10.1111/j.1346-8138.2010.00951.x Palucka, 2005, Cross-regulation of TNF and IFN-alpha in autoimmune diseases, Proc Natl Acad Sci U S A, 102, 3372, 10.1073/pnas.0408506102 Ettefagh, 2004, Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles, Arch Dermatol, 140, 1012, 10.1001/archderm.140.8.1012-a Posten, 2005, Recurrence of alopecia areata in a patient receiving etanercept injections, Arch Dermatol, 141, 759, 10.1001/archderm.141.6.759 Garcia Bartels, 2006, Development of alopecia areata universalis in a patient receiving adalimumab, Arch Dermatol, 142, 1654, 10.1001/archderm.142.12.1654 Hernandez, 2009, Development of alopecia areata after biological therapy with TNF-alpha Blockers: description of a case and review of the literature, Clin Exp Rheumatol, 27, 892 Pelivani, 2008, Alopecia areata universalis elicited during treatment with adalimumab, Dermatology, 216, 320, 10.1159/000113945 Chaves, 2008, Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab), Dermatology, 217, 380, 10.1159/000162180 Fabre, 2008, Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab, Dermatology, 216, 185, 10.1159/000111523 Ferran, 2011, Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-alpha blocker agents: Report of five cases and review of the literature, J Eur Acad Dermatol Venereol, 25, 479, 10.1111/j.1468-3083.2010.03770.x Tosti, 2006, Alopecia areata during treatment with biologic agents, Arch Dermatol, 142, 1653, 10.1001/archderm.142.12.1653 Strober, 2005, Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study, J Am Acad Dermatol, 52, 1082, 10.1016/j.jaad.2005.03.039 Pontikaki, 2012, Skin Manifestations Induced by TNF-Alpha Inhibitors in Juvenile Idiopathic Arthritis, Clin Rev Allergy Immunol, 42, 131, 10.1007/s12016-011-8262-2 Mohan, 2004, Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents, J Rheumatol, 31, 1955 Fujikawa, 2010, Cutaneous vasculitis induced by TNF inhibitors: a report of three cases, Mod Rheumatol, 20, 86, 10.1007/s10165-009-0232-7 Ramirez-Hernandez, 2005, Infliximab-induced vitiligo, Dermatology, 210, 79, 10.1159/000081494 Lahita, 2011, Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti-tumor necrosis factor therapy, J Rheumatol, 38, 579, 10.3899/jrheum.100968 Hernandez, 2011, Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists, Rheumatology (Oxford), 50, 1523, 10.1093/rheumatology/ker144 Hall, 2006, Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor, Arthritis Rheum, 55, 982, 10.1002/art.22358 Ishikawa, 2010, Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature, Clin Rheumatol, 29, 563, 10.1007/s10067-009-1370-1 Greenberg, 2005, Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis, Ann Neurol, 57, 664, 10.1002/ana.20464 Ramirez, 2011, Morphea associated with the use of adalimumab: a case report and review of the literature, Mod Rheumatol Ranganathan, 2005, Infliximab-induced scleredema in a patient with rheumatoid arthritis, J Clin Rheumatol, 11, 319, 10.1097/01.rhu.0000191162.66288.27 Mattozzi, 2010, Morphea, an unusual side effect of anti-TNF-alpha treatment, Eur J Dermatol, 20, 400, 10.1684/ejd.2010.0946 Zulian, 2008, New developments in localized scleroderma, Curr Opin Rheumatol, 20, 601, 10.1097/BOR.0b013e328309a5eb Kurzinski, 2011, Cytokine profiles in localized scleroderma and relationship to clinical features, Cytokine, 55, 157, 10.1016/j.cyto.2011.04.001 Voulgari, 2008, Granuloma annulare induced by anti-tumour necrosis factor therapy, Ann Rheum Dis, 67, 567, 10.1136/ard.2007.075663 Asarch, 2009, Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists, J Am Acad Dermatol, 61, 104, 10.1016/j.jaad.2008.09.032 Fernandez-Torres, 2010, Infliximab-induced lichen planopilaris, Ann Pharmacother, 44, 1501, 10.1345/aph.1P079 Boussemart, 2010, Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports, Dermatology, 221, 201, 10.1159/000318008 Kluk, 2011, Drug-induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept, Clin Exp Dermatol, 36, 871, 10.1111/j.1365-2230.2011.04102.x Bordignon, 2009, Bullous pemphigoid during long-term TNF-alpha blocker therapy, Dermatology, 219, 357, 10.1159/000243805